Results 151 to 160 of about 114,353 (299)

Challenges of Dengue in Hematological Disease Patients: Descriptive Analysis From the DANGO Registry During the 2023–2024 Outbreak in Argentina

open access: yesTransplant Infectious Disease, EarlyView.
During the 2023–2024 Argentine dengue outbreak, 33 patients with hematological disease showed high complication rates, frequent hospitalization (64%), severe thrombocytopenia (90%), and 6% dengue‐attributable mortality. Transfusion‐associated cases were documented.
Gustavo Adolfo Méndez   +16 more
wiley   +1 more source

Evaluation of Serum Ferritin Levels and Their Correlation With Clinical Outcomes in Dengue Virus Infection in a Population of Older Adults

open access: yesTropical Medicine &International Health, EarlyView.
ABSTRACT Objectives Prior studies have associated elevated ferritin levels with worse dengue outcomes but data from older adults remain limited. The aim of this study is to evaluate the serum ferritin levels and their correlation with disease severity in a population of older adults.
Sacha Orberg Temer   +3 more
wiley   +1 more source

The effectiveness of aerobic exercise on pain and disability in individuals with neck pain: A systematic review and meta‐analysis

open access: yesExperimental Physiology, EarlyView.
Abstract The present review aimed to investigate the effectiveness of aerobic exercise (AE) compared to other interventions in decreasing pain intensity and reducing disability in individuals with neck pain. A systematic review (SR) of randomized controlled trials was conducted. This SR was registered in PROSPERO (CRD42021231231).
Ana lzabela Sobral de Oliveira‐Souza   +9 more
wiley   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2440-2451, 1 May 2026.
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel   +21 more
wiley   +1 more source

myalgia

open access: yes
Citation: 'myalgia' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.15905 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 997-1004, April 2026.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy